期刊文献+

γ-氨基丁酸与其突变受体的相互作用

Interaction Between GABA and Mutant GABAaR
在线阅读 下载PDF
导出
摘要 采用同源建模技术构建了大鼠γ-氨基丁酸a型受体(GABAaR)模型及β97Tyr突变受体模型.采用分子对接技术研究了γ-氨基丁酸(GABA)与突变前后受体的相互作用.计算结果显示,突变及未突变受体之间在氢键作用和对接能量方面存在显著差异,配体与突变受体的结合能力随突变残基中氟原子数目的增加而降低. The interaction between receptor and ligand may explain the mechanism of ligand effect. Homology modeling is one of important technologies in computer-aided drug design. In this paper, a rat γ-aminobutyric acid receptor(GABAaR) model and its β97Tyr mutant receptor models were built by homology modeling. The calculation results show that the interactions between γ-aminobutyric acid(GABA) and the GABAaR and its mutants are significantly different in the docking energy and hydrogen bonds. As the numbers of fluorine atom in mutant receptors increase, the binding capacities between the receptors and ligand decrease.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2012年第11期2462-2469,共8页 Chemical Journal of Chinese Universities
基金 国家自然科学基金(批准号:20872093 21172147 21072216) 上海市教委创新项目(批准号:11ZZ112) 国家科技部"十二五"支撑项目(批准号:2011BAE06B05) 国家基础研究重点项目(批准号:2010CB126106 2010CB126103)资助
关键词 γ-氨基丁酸a型受体 活性位点 氨基酸突变 同源建模 分子对接 γ-Aminobutyric acid receptor(GABAaR) Active site Mutations of amino acid Homology modeling Docking
  • 相关文献

参考文献56

  • 1Barnard E. A. . Trends Biochem. Sci. [J], 1992, 17: 368-374.
  • 2Ci S. Q. , Ren T. R. , Ma C. X. , Su Z. G. . J. Mol. Graph. Model. [J], 2007, 26: 537-545.
  • 3Korpi E. R. , Grunder G. , Luddens H. . Prog. Neurobiol. [J], 2002, 67: 113-159.
  • 4Minier F. , Sigel E. . PNAS[J], 2004, 101: 7769-7774.
  • 5Andrea C. , Germano G. , Salvatore V. , Maurizio A. , Salvatore V. , Gianluca G. , Cristiana S. , Elisabetta M. , Giovanni B. , Alessan-dra C. . Bioorg. Med. Chem. [J], 2008, 16: 3428-3437.
  • 6Stkphane M. J. , Pascal C. , Catherine R. , Daniel G. , Danielle V. G. , Jacques C. , Pierre B. , Pierre T. . Med. Chem. [J], 1994,37: 2153-2160.
  • 7Cox E. D. , HDiaz-Arauzo H. , Huang Q. , Reddy M. S. , Ma C. R. , Harris B. , McKernan R. , Skolnick P. , Cook J. M. . Med.Chem. [J], 1998, 41: 2537-2552.
  • 8Huang Q. , He X. H. , Ma C. H. , Liu R. Y. , Yu S. , Dayer C. A. , Wenger G. R. , McKernan R. , Cook J. M. . Med. Chem. [J],2000, 43: 71-95.
  • 9Mohammad S. A. , Ryu K. , Hiromi H. , Kong X. Y. , Ozoe F. , Yoshihisa M. , Fumio M. , Ozoe Y. . J. Agric. Food Chem. [J],2006, 54: 1361-1372.
  • 10Zhang P. W. , Zhang W. J. , Liu R. Y. , Harris B. , Skolnick P. , Cook J. M. . Med. Chem. [J], 1995, 38: 1679-1688.

二级参考文献31

  • 1Elias J.A.,Lee C.G.,Zheng T.,Ma B.,Homer R.J.,Zhu Z..J.Clin.Invest.[J],2003,111:291-297.
  • 2Luster A.D..N.Engl.J.Med.[J],1998,338:436-445.
  • 3Baggiolini M.,Dewald B.,Moser B..Annu.Rev.Immunol.[J],1997,15:675-705.
  • 4Murphy P.M.,Baggiolini M.,Charo I.F.,Hébert C.A.,Horuk R.,Matsushima K.,Miller L.H.,Oppenheim J.J.,Power C.A..Pharmacol.Rev.[J],2000,52:145-176.
  • 5Ponath P.D.,Qin S.,Ringler D.J.,Clark-Lewis I.,Wang J.,Kassam N.,Smith H.,Shi X.,Gonzalo J.A.,Newman W.,Gutierrez-Ramos J.C.,Mackay C.R..J.Clin.Invest.[J],1996,97:604-612.
  • 6Uguccioni M.,Mackay C.R.,Ochensberger B.,Loetscher P.,Rhis S.,LaRosa G.J.,Rao P.,Ponath D.P.,Baggiolini M.,Dahinden A.C..J.Clin.Invest.[J],1997,100:1137-1143.
  • 7Sallusto F.,Mackay C.R.,Lanzavecchia A..Science[J],1997,277:2005-2007.
  • 8Pruitt J.R.,Batt D.G.,Wacker D.A.,Bostrom L.L.,Booker S.K.,McLaughlin E.,Houghton G.C.,Varnes J.G.,Christ D.D.,Covington M.,Das A.M.,Davies P.,Graden D.,Kariv I.,Orlovsky Y.,Stowell N.C.,Vaddi K.G.,Wadman E.A.,Welch P.K.,Yeleswaram S.,Solomon K.A.,Newton R.C.,Decicco C.P.,Carter P.H.,Ko S.S..Bioorg.Med.Chem.Lett.[J],2007,17:2992-2997.
  • 9Morokata T.,Suzuki K.,Masunaga Y.,Taguchi K.,Morihira K.,Sato I.,Fujii M.,Takizawa S.,Torii Y.,Yamamoto N.,Kaneko M.,Yamada T.,Takahashi K.,Shimizu Y..J.Pharmacol.Expt.Ther.[J],2006,317:244-250.
  • 10Wise E.L.,Duchesnes C.,da Fonseca P.C.,Allen R.A.,Williams T.J.,Pease J.E..J.Biol.Chem.[J],2007,282:27935-27943.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部